Looking at those patients who presented with an SHH activated medulloblastoma aged 3.5 years and younger as well as assuming SHH activation for all our Gorlin patients, approximately 17% of them would have tested positive for a pathogenic PTCH1 or SUFU mutation. The gene discussed is SHH; the disease is medulloblastoma.